Skip to main
ALLR
ALLR logo

Allarity Therapeutics (ALLR) Stock Forecast & Price Target

Allarity Therapeutics (ALLR) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Allarity Therapeutics Inc is positioned favorably due to its innovative approach in developing stenoparib, which has demonstrated significant clinical benefits for patients with advanced recurrent ovarian cancer and limited treatment options. The company's proprietary Drug Response Predictor (DRP) technology enhances patient selection, potentially leading to improved outcomes that could drive revenue growth. Current valuations suggest an attractive investment opportunity, with a notable upside anticipated based on net present value (NPV) analysis, indicating a promising financial horizon for the company's stock.

Bears say

Allarity Therapeutics Inc reported a net loss of $2.37 million, translating to an earnings per share (EPS) of $(0.15), which fell short of estimates by $(0.06), highlighting ongoing financial challenges. The company's outlook is further strained by significant risks including potential balance sheet and liquidity issues, along with the possibility that its product candidates may fail to demonstrate necessary safety and efficacy in clinical trials and post-market settings. Additional concerns arise from the competitive landscape, regulatory hurdles, and changing macroeconomic factors that may impede growth and investor sentiment towards the biotech sector.

Allarity Therapeutics (ALLR) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allarity Therapeutics (ALLR) Forecast

Analysts have given Allarity Therapeutics (ALLR) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Allarity Therapeutics (ALLR) has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allarity Therapeutics (ALLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.